Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma

  • Authors:
    • Chueh‑Chuan Yen
    • San‑Chi Chen
    • Giun‑Yi Hung
    • Po‑Kuei Wu
    • Wei‑Yang Chua
    • Yung‑Chan Lin
    • Chiao‑Han Yen
    • Yen‑Chun Chen
    • Jir‑You Wang
    • Muh‑Hwa Yang
    • Yee Chao
    • Ming‑Chau Chang
    • Wei‑Ming Chen
  • View Affiliations

  • Published online on: August 23, 2019     https://doi.org/10.3892/ijo.2019.4861
  • Pages: 938-948
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Liposarcoma (LPS) is one of the most frequently reported type of soft‑tissue sarcoma (STS). Well‑differentiated (WD) LPS and dedifferentiated (DD) LPS are the two most common subtypes. Chemotherapy has been considered to be ineffective in LPS, and novel treatment agents are thus necessary. In this study, we reanalyzed two published microarray data sets of LPS. By comparing the top 50 upregulated genes in DD LPS in both sets of data, we identified 12 overlapping genes. Of note, the top five gene sets enriched in DD LPS in both sets of data were involved in cell cycle regulation. Among the 12 overlapping genes, aurora kinase A (AURKA) is a well‑known gene involved in cell cycle regulation; we thus further investigated this gene. AURKA was significantly upregulated in DD LPS, compared with WD LPS. Among 40 cases of DD LPS in GSE30929, patients with high AURKA expression in tumors had significantly worse distant recurrence‑free survival than those with low expression. In an in vitro model, MLN8237, an AURKA inhibitor, could inhibit AURKA in LPS cell lines with a resultant G2/M arrest. MLN8237 was also reported to exert a cytotoxic effect by inducing apoptosis in LPS cell lines. Furthermore, except for cisplatin, MLN8237 had a significantly synergistic effect with chemotherapy agents against LPS. MLN8237 induced cellular senescence in LPS cell lines with increased expression of DcR2, a senescence biomarker, and upregulated expression of cytokines associated with the senescence‑associated secretory phenotype, including interleukin (IL)‑1α, IL‑6 and IL‑8. Our study identified AURKA as a potential biomarker for predicting poor prognosis in LPS. The findings of the present study suggested the potential of AURKA as a therapeutic target in LPS cell line models, while the novel combination of AURKA inhibitors and chemotherapy requires further investigation.

References

1 

Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI

2 

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet. 368:1329–1338. 2006. View Article : Google Scholar : PubMed/NCBI

3 

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, et al: Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 26:620–625. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, et al: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:295–302. 2013. View Article : Google Scholar

5 

McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S and Fletcher JA: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 23:866–873. 2005. View Article : Google Scholar : PubMed/NCBI

6 

Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, et al: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 363:1727–1733. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Chibon F, Lagarde P, Salas S, Pérot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, et al: Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 16:781–787. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Yen CC, Yeh CN, Cheng CT, Jung SM, Huang SC, Chang TW, Jan YY, Tzeng CH, Chao TC, Chen YY, et al: Integrating bioin-formatics and clinicopathological research of gastrointestinal stromal tumors: Identification of aurora kinase A as a poor risk marker. Ann Surg Oncol. 19:3491–3499. 2012. View Article : Google Scholar : PubMed/NCBI

9 

Yeh CN, Yen CC, Chen YY, Cheng CT, Huang SC, Chang TW, Yao FY, Lin YC, Wen YS, Chiang KC, et al: Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. Oncotarget. 5:4071–4086. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Hung GY, Yen CC, Horng JL, Liu CY, Chen WM, Chen TH and Liu CL: Incidences of primary soft tissue sarcoma diagnosed on extremities and trunk wall: A population-based study in Taiwan. Medicine (Baltimore). 94:e16962015. View Article : Google Scholar

11 

Liu CY, Yen CC, Chen WM, Chen TH, Chen PC, Wu HT, Shiau CY, Wu YC, Liu CL and Tzeng CH: Soft tissue sarcoma of extremities: The prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence. Ann Surg Oncol. 17:2102–2111. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Italiano A, Toulmonde M, Cioffi A, Penel N, Isambert N, Bompas E, Duffaud F, Patrikidou A, Lortal B, Le Cesne A, et al: Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival. Ann Oncol. 23:1601–1607. 2012. View Article : Google Scholar

13 

Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, et al: Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 67:6626–6636. 2007. View Article : Google Scholar : PubMed/NCBI

14 

Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, et al: Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferen-tiated liposarcoma. J Clin Oncol. 31:2024–2028. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Gobble RM, Qin LX, Brill ER, Angeles CV, Ugras S, O'Connor RB, Moraco NH, Decarolis PL, Antonescu C and Singer S: Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res. 71:2697–2705. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Li C and Hung Wong W: Model-based analysis of oligonucleotide arrays: Model validation, design issues and standard error application. Genome Biol. 2:RESEARCH00322001.PubMed/NCBI

17 

Li C and Wong WH: Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci USA. 98:31–36. 2001. View Article : Google Scholar : PubMed/NCBI

18 

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI

19 

Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 34:267–273. 2003. View Article : Google Scholar : PubMed/NCBI

20 

Chou YS, Yen CC, Chen WM, Lin YC, Wen YS, Ke WT, Wang JY, Liu CY, Yang MH, Chen TH and Liu CL: Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel. Int J Oncol. 48:1187–1194. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI

22 

Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI

23 

Schmit TL, Nihal M, Ndiaye M, Setaluri V, Spiegelman VS and Ahmad N: Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis. Cancer Res. 72:3864–3872. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Zhu Y, Xu L, Zhang J, Hu X, Liu Y, Yin H, Lv T, Zhang H, Liu L, An H, et al: Sunitinib induces cellular senescence via p53/ Dec1 activation in renal cell carcinoma cells. Cancer Sci. 104:1052–1061. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Muller-Tidow C, Metzger R, Kügler K, Diederichs S, Idos G, Thomas M, Dockhorn-Dworniczak B, Schneider PM, Koeffler HP, Berdel WE and Serve H: Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 61:647–653. 2001.PubMed/NCBI

26 

Lens SM, Voest EE and Medema RH: Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer. 10:825–841. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ and Carew JS: The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med. 15:2057–2070. 2011. View Article : Google Scholar

28 

Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Persky AM, Miller TP and Mahadevan D: Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol. 81:881–890. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Kuilman T and Peeper DS: Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer. 9:81–94. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, et al: Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet. 387:1629–1637. 2016. View Article : Google Scholar : PubMed/NCBI

31 

Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M and Chawla S: Activity of eribulin in patients with advanced lipo-sarcoma demonstrated in a subgroup analysis from a randomized phase III study of Eribulin versus dacarbazine. J Clin Oncol. 35:3433–3439. 2017. View Article : Google Scholar : PubMed/NCBI

32 

Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, et al: Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial. J Clin Oncol. 34:786–793. 2016. View Article : Google Scholar :

33 

Chu CY, Chen CF, Rajendran RS, Shen CN, Chen TH, Yen CC, Chuang CK, Lin DS and Hsiao CD: Overexpression of Akt1 enhances adipogenesis and leads to lipoma formation in zebrafish. PLoS One. 7:e364742012. View Article : Google Scholar : PubMed/NCBI

34 

Fletcher CD, Akerman M, Dal Cin P, de Wever I, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, et al: Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the chromosomes and morphology (CHAMP) Collaborative study group. Am J Pathol. 148:623–630. 1996.PubMed/NCBI

35 

Dei Tos AP, Doglioni C, Piccinin S, Sciot R, Furlanetto A, Boiocchi M, Dal Cin P, Maestro R, Fletcher CD and Tallini G: Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol. 190:531–536. 2000. View Article : Google Scholar : PubMed/NCBI

36 

Lagarde P, Perot G, Kauffmann A, Brulard C, Dapremont V, Hostein I, Neuville A, Wozniak A, Sciot R, Schoffski P, et al: Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res. 18:826–838. 2012. View Article : Google Scholar

37 

Dickson MA, Mahoney MR, Tap WD, D'Angelo SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Nair JS and Schwartz GK: Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol. 27:1855–1860. 2016. View Article : Google Scholar : PubMed/NCBI

38 

Huck JJ, Zhang M, McDonald A, Bowman D, Hoar KM, Stringer B, Ecsedy J, Manfredi MG and Hyer ML: MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res. 8:373–384. 2010. View Article : Google Scholar : PubMed/NCBI

39 

Campisi J and d'Adda di Fagagna F: Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol. 8:729–740. 2007. View Article : Google Scholar : PubMed/NCBI

40 

Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 92:9363–9367. 1995. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 55 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yen, C., Chen, S., Hung, G., Wu, P., Chua, W., Lin, Y. ... Chen, W. (2019). Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma. International Journal of Oncology, 55, 938-948. https://doi.org/10.3892/ijo.2019.4861
MLA
Yen, C., Chen, S., Hung, G., Wu, P., Chua, W., Lin, Y., Yen, C., Chen, Y., Wang, J., Yang, M., Chao, Y., Chang, M., Chen, W."Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma". International Journal of Oncology 55.4 (2019): 938-948.
Chicago
Yen, C., Chen, S., Hung, G., Wu, P., Chua, W., Lin, Y., Yen, C., Chen, Y., Wang, J., Yang, M., Chao, Y., Chang, M., Chen, W."Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma". International Journal of Oncology 55, no. 4 (2019): 938-948. https://doi.org/10.3892/ijo.2019.4861